- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04937673
The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Camrelizumab Combined With Chemotherapy for Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma:A Phase II Clinical Study to Explore the Relationship Between Biomarkers and Efficacy
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100142
- Department of GI Oncology, Peking University Cancer Hospital,
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age: 18-75 years old, male or female;
- Esophageal squamous cell carcinoma was confirmed by pathology (except for cervical and Suprathoracic tumors that could not be operated);
- Patients with resectable esophageal squamous cell carcinoma with clinical stage T3-T4a or TxN + M0 (except T4b);
- ECOG PS score was 0-1;
- There was at least one measurable lesion (according to recist1.1) or unmeasurable lesion that could be evaluated, and the imaging diagnosis time was ≤ 21 days;
- The expected survival time was more than 3 months;
The function of the main organs was normal, and there were no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities and immunodeficiency diseases. The laboratory examination meets the following requirements:
- Hemoglobin (Hb) ≥ 90g / L;
- WBC ≥ 3.0 × 109/L; Neutrophil count (NEUT) ≥ 1.5 × 109/L;
- Platelet count (PLT) ≥ 100 × 109/L;
- Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance rate ≥ 50 ml / min (Cockcroft Gault formula);
- Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);
- The levels of AST and ALT were less than 2.5 times the upper limit of normal (ULN);
There was no active bleeding or thrombosis
- International normalized ratio INR ≤ 1.5 × ULN;
- Partial thromboplastin time APTT ≤ 1.5 × ULN;
- Prothrombin time Pt ≤ 1.5ULN;
- The patients with normal or mild to moderate abnormal lung function (VC% > 60%, FEV1 > 1.2L, FEV1% > 40%, DLco> 40%) could tolerate esophagectomy;
- The fertile female subjects were required to conduct blood pregnancy test within 72 hours before the first administration, and the result was negative, and voluntarily used appropriate contraceptive methods during the observation period and within 90 days after the last administration of the study drug; For men, surgical sterilization or consent to appropriate contraceptive methods during the observation period and within 90 days after the last administration of the study drug should be used.
- The subjects voluntarily joined the study and signed the informed consent form (ICF);
- The patients with good compliance were expected to follow up the efficacy and adverse events / reactions according to the protocol requirements.
Exclusion Criteria:
- Subjects who have received or are receiving additional chemotherapy, radiotherapy, targeted or immunotherapy;
- Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy)); The subjects with childhood asthma who had been completely relieved and did not need any intervention or vitiligo in adulthood could be included, but the subjects who needed bronchodilator for medical intervention could not be included;
- Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody positive and HCV-RNA higher than the detection limit of the analytical method), or co infection of hepatitis B and hepatitis C;
- Immunosuppressive drugs were used within 14 days before the first use of the study drug, excluding nasal and inhaled corticosteroids or physiological doses of systemic corticosteroids;
- Live attenuated vaccine was inoculated within 4 weeks before the first administration or during the study period;
- Patients with hypertension who can not be reduced to normal range after antihypertensive drug treatment (systolic blood pressure ≤ 140 mmHg / diastolic blood pressure ≤ 90 mmHg);
- Subjects with uncontrollable clinical cardiac symptoms or diseases, such as (1) heart failure of NYHA II or above (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention;
- Severe infection (e.g. need for intravenous antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or fever of unknown origin > 38.5% occurred during the screening period / before the first administration;
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation is known;
- Pregnant or lactating women; The fertile subjects were unwilling or unable to take effective contraceptive measures;
- Other malignant tumors were found in the past or at the same time, but the cured basal cell carcinoma of skin, carcinoma in situ of cervix and carcinoma in situ of breast were excluded;
- Known to have allergic history to the drug components of this protocol;
- Other situations considered unsuitable by the researchers.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Camrelizumab+ Paclitaxel+ Cisplatin
The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1.
Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation).
At the end of the treatment, the patients were followed up for safety and effectiveness.
|
Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks. Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks. Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks. |
Eksperimentel: Camrelizumab+ Albumin bound paclitaxel+ Cisplatin
The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1.
Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation).
At the end of the treatment, the patients were followed up for safety and effectiveness.
|
Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks. Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks. Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
biomarkers related to pCR
Tidsramme: 9 weeks
|
t has a good value in predicting the efficacy of immunotherapy, and is helpful for the accurate formulation of treatment plan and the accurate evaluation of prognosis of patients with esophageal cancer.
|
9 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Objective Response Rate
Tidsramme: 9 weeks
|
Assess ORR, defined as Investigator-assessed CR + PR, per RECIST 1.1.
|
9 weeks
|
Disease Control Rate
Tidsramme: 9 weeks
|
Percentage of patients with CR/PR/SD in the number of patients that whose tumour can be evaluated.
|
9 weeks
|
Disease free survival
Tidsramme: Time from randomization to patient's tumor progression or death
|
The DFS will be defined as the time of patients alive without local recurrence or distant metastasis of disease from the date of the administration of treatment.
|
Time from randomization to patient's tumor progression or death
|
Overall Survival
Tidsramme: The time from the beginning of randomization to death due to any cause.
|
OS is defined as the time from registration to death due to any cause, or censored at date last known alive.
Measured by the method of Kaplan and Meier
|
The time from the beginning of randomization to death due to any cause.
|
Safety
Tidsramme: from first treatment to 90 days after esophagectomy
|
Adverse events
|
from first treatment to 90 days after esophagectomy
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Neoplasmer, kirtel og epitel
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Neoplasmer i hoved og hals
- Esophageale sygdomme
- Neoplasmer, pladecelle
- Esophageale neoplasmer
- Karcinom
- Karcinom, pladecelle
- Esophageal pladecellekarcinom
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Antineoplastiske midler, fytogene
- Paclitaxel
- Cisplatin
- Albumin-bundet Paclitaxel
Andre undersøgelses-id-numre
- MA-EC-II-005
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Thorax esophageal pladecellecarcinom
-
Shandong UniversityUkendtEsophageal Squamous Intraepithelial NeoplasiaKina
-
Fujian Medical University Union HospitalIkke rekrutterer endnuEsophageal pladecellecarcinom Thoracic Stadium II | Esophageal pladecellecarcinom Thoracic Stadium III | Esophageal pladecellecarcinom Thoracic Stadium IVKina
-
Shanghai Henlius BiotechRekrutteringESCC eller Esophageal Adenosquamous CarcinomaKina
-
Merck Sharp & Dohme LLCAktiv, ikke rekrutterendeEsophageal pladecellekarcinom (ESCC) | Gastroøsofageal Junction Carcinoma (GEJC) | Esophageal Adenocarcinom (EAC)Kina, Canada, Forenede Stater, Argentina, Belgien, Brasilien, Chile, Tjekkiet, Danmark, Estland, Frankrig, Tyskland, Guatemala, Hong Kong, Ungarn, Italien, Japan, Korea, Republikken, Mexico, Peru, Filippinerne, Portugal, Rumænien, Den... og mere
-
Fudan UniversityAktiv, ikke rekrutterendeOligorecurrent og Oligometastatic Esophageal Squamous Cell CarcinomKina
-
The First Affiliated Hospital of Henan University...Ikke rekrutterer endnuEsophageal Carcinoma in Situ AJCC V7
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RekrutteringPeritoneal karcinomatose | Neoplasma i fordøjelsessystemet | Lever og intrahepatisk galdekanalcarcinom | Appendix Carcinoma af AJCC V8 Stage | Kolorektalt karcinom af AJCC V8 Stage | Esophageal Carcinoma af AJCC V8 Stage | Gastrisk karcinom af AJCC V8 StageForenede Stater
-
Peking University Cancer Hospital & InstituteUkendtEsophageal pladecellekarcinom | Mild dysplasi i spiserøret | Moderat dysplasi i spiserøret | Alvorlig dysplasi i spiserøret | Carcinoma in situ i spiserøretKina
-
Incyte CorporationAktiv, ikke rekrutterendeLivmoderhalskræft | Nasopharyngealt karcinom | Avancerede solide tumorer | Mesotheliom | Småcellet lungekræft | Esophageal pladecellekarcinom | Merkel cellekarcinom | Sarcomatoid nyrecellekarcinom | Anal karcinom | Kutant planocellulært karcinom | MSI-H/dMMR-tumorer | PD-L1 amplificeret tumor (9p24.1) | Urothelial... og andre forholdFinland, Forenede Stater, Det Forenede Kongerige, Belgien, Sverige, Danmark, Norge
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeOndartet fast neoplasma | Nasopharyngealt karcinom | Adenoid cystisk karcinom | Overgangscellekarcinom | Cholangiocarcinom | Intrahepatisk cholangiocarcinom | Chordoma | Gestationel trofoblastisk tumor | Pseudomyxoma Peritonei | Cervikal Adenocarcinom | Vaginalt Adenocarcinom | Vaginalt planocellulært karcinom,... og andre forholdForenede Stater, Guam
Kliniske forsøg med Camrelizumab+ Paclitaxel+ Cisplatin
-
Guangdong Association of Clinical TrialsIkke rekrutterer endnu
-
Jiangsu HengRui Medicine Co., Ltd.AfsluttetAvanceret esophageal cancerKina
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... og andre samarbejdspartnereIkke rekrutterer endnuLivmoderhalskræft | Lokalt avanceret livmoderhalskræft | PD-L1 negativ | Neoadjuverende kemoimmunterapiKina
-
Henan Cancer HospitalRekrutteringPlanocellulært karcinom i hudenKina
-
The First Affiliated Hospital of Zhengzhou UniversityJiangsu HengRui Medicine Co., Ltd.Ikke rekrutterer endnu
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... og andre samarbejdspartnereIkke rekrutterer endnuLivmoderhalskræft | Bevarelse af fertilitet | Neoadjuverende kemoimmunterapiKina
-
Tianjin Medical University Cancer Institute and...RekrutteringLokalt avanceret livmoderhalskræftKina
-
Guangzhou Institute of Respiratory DiseaseJiangsu HengRui Medicine Co., Ltd.; BGI-ShenzhenAfsluttetEsophageal pladecellekarcinom | ImmunterapiKina
-
Fujian Medical University Union HospitalIkke rekrutterer endnuKemoterapi | StråleterapiKina
-
Tianjin Medical University Cancer Institute and...Rekruttering